GlassScriptPhysician profile
Rachel Tiu
NPI 1780268979
$19,149.88
in general payments reported to CMS, 2019-2025
31 companies · $1,886 in 2025
The $1,886 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,204 · 2022: $8,284 · 2023: $2,553 · 2024: $2,223 · 2025: $1,886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,600 · Education: $61.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,600.49 |
| Education | $61.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $5,563.25 | 2021-2022 | |
| Abbvie INC. | $3,531.41 | 2021-2025 | |
| Amgen INC. | $1,951.32 | 2021-2025 | Tavneos, Otezla, Enbrel |
| Janssen Biotech, INC. | $1,542.97 | 2021-2024 | Tremfya, Simponi Aria, Stelara |
| Novartis Pharmaceuticals Corporation | $1,096.35 | 2021-2025 | |
| Ucb, INC. | $967.35 | 2021-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $905.69 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $772.74 | 2021-2024 | Lupkynis |
| Glaxosmithkline, LLC. | $498.10 | 2021-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $332.64 | 2021-2025 | Orencia |
| Organon LLC | $308.57 | 2021-2025 | Hadlima, Renflexis |
| Lilly USA, LLC | $297.47 | 2021-2024 | Taltz |
| Horizon Therapeutics Plc | $195.02 | 2021-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.92 | 2021-2025 | Cyltezo, Ofev, Jascayd |
| Genentech USA, INC. | $161.73 | 2024-2025 | Actemra, Gazyva |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $157.94 | 2021-2022 | |
| Fresenius Kabi USA, LLC | $144.36 | 2023-2024 | Idacio |
| Sanofi-Aventis U.S. LLC | $137.99 | 2021-2022 | |
| Celltrion USA INC. | $61.21 | 2023 | Yuflyma |
| Mallinckrodt Hospital Products INC. | $60.87 | 2022-2024 | Acthar |
| Scilex Pharmaceuticals INC. | $52.71 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $35.79 | 2023 | Arcalyst |
| Genzyme Corporation | $32.62 | 2025 | |
| Mylan Institutional INC. | $24.69 | 2023 | |
| Sobi, INC | $22.76 | 2022 | |
| Fidia Pharma USA INC. | $22.38 | 2024 | Hymovis, Hyalgan, Triluron |
| Sandoz INC. | $19.17 | 2025 | Hyrimoz |
| Bioventus LLC | $18.29 | 2021 | |
| Ferring Pharmaceuticals INC. | $15.41 | 2022 | |
| Alexion Pharmaceuticals, INC. | $14.57 | 2021 | |
| Merck Sharp & Dohme LLC | $11.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Tiu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.